



Financial Results (Consolidated) for the Fiscal Year ended March 31, 2022

FUJIFILM Holdings Corporation

Teichi Goto

President and Chief Executive Officer

Date of annual shareholders' meeting: June 29, 2022

Projected date of annual securities report: June 30, 2022

Reference materials regarding operating results of the current fiscal year to be prepared: Yes

Meeting to explain operating results of the current fiscal year to be held: Yes

(Consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America.)

May 11, 2022

URL: <https://holdings.fujifilm.com/en>

Projected date of the beginning of cash dividends: June 30, 2022

1. Results of the Fiscal Year ended March 31, 2022 (From April 1, 2021 to March 31, 2022)

(1) OPERATING RESULTS

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen
%: Changes from the corresponding period of the previous fiscal year

	Revenue		Operating income		Income before income taxes		Net income attributable to FUJIFILM Holdings	
		%		%		%		%
Year ended March 31, 2022	2,525,773	15.2	229,702	38.8	260,446	10.4	211,180	16.5
Year ended March 31, 2021	2,192,519	(5.3)	165,473	(11.3)	235,870	36.3	181,205	45.0

Note: Comprehensive income

Year ended March 31, 2022 ¥ 347,136 million (17.2%)

Year ended March 31, 2021 ¥ 296,226 million (235.5%)

	Net income attributable to FUJIFILM Holdings per share	Net income attributable to FUJIFILM Holdings per share (Assuming full dilution)	Return on FUJIFILM Holdings shareholders' equity	Ratio of income before income taxes to total assets	Ratio of operating income to revenue
	Yen	Yen	%	%	%
Year ended March 31, 2022	527.33	526.11	9.0	6.9	9.1
Year ended March 31, 2021	453.28	451.75	8.7	6.9	7.5

(Ref) Equity in net earnings of affiliated companies

Year ended March 31, 2022 ¥ 13,128 million

Year ended March 31, 2021 ¥ 3,198 million

(2) FINANCIAL POSITION

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

	Total assets	Total equity (Net asset)	FUJIFILM Holdings shareholders' equity	FUJIFILM Holdings shareholders' equity ratio to total assets	FUJIFILM Holdings shareholders' equity per share
				%	Yen
Year ended March 31, 2022	3,955,280	2,524,940	2,502,657	63.3	6,244.29
Year ended March 31, 2021	3,549,203	2,222,157	2,204,566	62.1	5,514.14

(3) CASH FLOWS

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

	Net Cash provided by Operating Activities	Net Cash used in Investing Activities	Net Cash used in Financing Activities	Cash and Cash Equivalents at the end of year
Year ended March 31, 2022	323,934	(153,542)	(105,184)	486,328
Year ended March 31, 2021	420,861	(279,381)	(163,093)	394,795

2. Cash Dividends

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

	Cash dividends per share					Total cash dividends	Consolidated payout ratio	Ratio of cash dividends to shareholders' equity
	1st Quarter	2nd Quarter	3rd Quarter	Year End	Year Total			
	Yen	Yen	Yen	Yen	Yen		%	%
Year ended March 31, 2021	-	47.50	-	52.50	100.00	39,979	22.1	1.9
Year ended March 31, 2022	-	55.00	-	55.00	110.00	44,086	20.9	1.9
Year ending March 31, 2023 (Forecast)	-	60.00	-	60.00	120.00		25.0	

3. Forecast for the Fiscal Year ending March 31, 2023 (From April 1, 2022 to March 31, 2023)

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen
%: Changes from the corresponding period of the previous fiscal year

	Revenue		Operating income		Income before income taxes		Net income attributable to FUJIFILM Holdings		Net income attributable to FUJIFILM Holdings per share
		%		%		%		%	Yen
Year ending March 31, 2023	2,650,000	4.9	245,000	6.7	255,000	(2.1)	192,000	(9.1)	479.05

Note: Net income attributable to FUJIFILM Holdings per share is calculated using the number of shares issued as of March 31, 2022 excluding treasury shares for the average number of shares for the relevant period.

Notes

(1) Changes in status of material subsidiaries during the period

(Company newly consolidated or removed from consolidation): None

(2) Changes in accounting principles

1. Changes in accounting policies accompanying amendment of accounting standards: None

2. Other changes in accounting policies: None

(3) Number of shares outstanding

1. Issued (including treasury stock):

2. Treasury stock:

3. Average number of shares:

As of March 31, 2022	514,625,728	As of March 31, 2021	514,625,728
As of March 31, 2022	113,834,546	As of March 31, 2021	114,823,247
Year ended March 31, 2022	400,387,264	Year ended March 31, 2021	399,762,945

(Reference) Summary of Financial Results (Non-Consolidated)

Results of the Fiscal Year ended March 31, 2022 (From April 1, 2021 to March 31, 2022)

(1) OPERATING RESULTS

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded down to the nearest million yen
%: Changes from the corresponding period of the previous fiscal year

	Revenue		Operating income		Ordinary income		Net income	
		%		%		%		%
Year ended March 31, 2022	43,862	41.5	28,184	13.2	34,482	29.7	32,685	24.6
Year ended March 31, 2021	30,995	(48.7)	24,907	(54.8)	26,584	(89.0)	26,234	(89.7)

	Net income per share of common stock	Net income per share of common stock (Assuming full dilution)
	Yen	Yen
Year ended March 31, 2022	81.62	81.43
Year ended March 31, 2021	65.62	65.39

(2) FINANCIAL POSITION

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded down to the nearest million yen

	Total assets	Net assets	Net asset ratio to total assets	Net assets per share of common stock
				Yen
Year ended March 31, 2022	1,695,782	1,243,055	73.1	3,093.84
Year ended March 31, 2021	1,741,422	1,252,676	71.7	3,121.03

(Reference) Shareholders' equity

Year ended March 31, 2022 ¥ 1,239,983 million

Year ended March 31, 2021 ¥ 1,247,796 million

Disclosure regarding the status of the year-end audit process

These Financial Results (Consolidated) for the Fiscal Year ended March 31, 2022 are out of scope for the year-end audit procedure by certified public accountants or audit firm.

Explanation of Appropriate Use of Forecast and Other Special Items

Statements regarding future events including forecasts of operating results are based on limited available information and reasonable assumptions as of today. The Company does not have the intention of guaranteeing the realization of future performance. Actual operating results are always subject to change significantly due to various matters. Assumptions for the forecast and warnings for users of the forecast are mentioned in the page 6, Outlook for the Fiscal Year ending March 31, 2023 of the section (1) Analysis of Results of Operations in 1. ANALYSIS OF OPERATING RESULTS AND CONSOLIDATED FINANCIAL POSITION.

[INDEX]

1.	ANALYSIS OF OPERATING RESULTS AND CONSOLIDATED FINANCIAL POSITION	
(1)	Analysis of Results of Operations	P.2
(2)	Analysis of Consolidated Financial Position	P.6
(3)	Basic Policy Regarding Distribution of Profits and Dividends Applicable to the Fiscal Year under Review and Subsequent Fiscal Year	P.7
2.	CORPORATE STRUCTURE OF FUJIFILM GROUP	P.7
3.	CORPORATE DIRECTION	P.7
4.	BASIC RATIONALE FOR SELECTION OF ACCOUNTING STANDARDS	P.11
5.	CONSOLIDATED FINANCIAL STATEMENTS	
(1)	Consolidated Balance Sheets	P.12
(2)	Consolidated Statements of Income and Consolidated Statements of Comprehensive Income	P.14
	(Consolidated Statements of Income)	P.14
	Year ended March 31	P.14
	Three months ended March 31	P.15
	(Consolidated Statements of Comprehensive Income)	P.16
	Year ended March 31	P.16
	Three months ended March 31	P.16
(3)	Consolidated Statements of Changes in Shareholders' Equity	P.17
(4)	Consolidated Statements of Cash Flows	P.18
(5)	Notes to Consolidated Financial Statements	P.19
	(Notes Relating to the Going Concern Assumption)	P.19
	(Summary of Significant Accounting Policies)	P.19
	(Segment Information)	P.20
	1) Year ended March 31	P.20
	2) Three months ended March 31	P.24
	(Amounts Per Share of Common Stock)	P.25
	(Subsequent Event)	P.25

1. ANALYSIS OF OPERATING RESULTS AND CONSOLIDATED FINANCIAL POSITION

(1) Analysis of Results of Operations

Amount Unit: Billions of yen

	Year ended March 31, 2022		Year ended March 31, 2021		Change (Amount)	Change (%)
	From April 1, 2021 to March 31, 2022	From April 1, 2021 to March 31, 2022	From April 1, 2020 to March 31, 2021	From April 1, 2020 to March 31, 2021		
Domestic revenue	39.3%	991.9	42.3%	927.9	64.0	6.9%
Overseas revenue	60.7%	1,533.9	57.7%	1,264.6	269.3	21.3%
Revenue	100.0%	2,525.8	100.0%	2,192.5	333.3	15.2%
Operating income	9.1%	229.7	7.5%	165.5	64.2	38.8%
Income before income taxes	10.3%	260.4	10.8%	235.9	24.5	10.4%
Net income attributable to FUJIFILM Holdings	8.4%	211.2	8.3%	181.2	30.0	16.5%
Exchange rates (Yen / US\$)		¥113		¥106	¥7	
Exchange rates (Yen / Euro)		¥131		¥124	¥7	

In the fiscal year ended March 31, 2022, the Fujifilm Group recorded ¥2,525.8 billion in consolidated revenue (up 15.2% year-over-year), reflecting sales increases mainly in the medical systems business, the bio CDMO business, the life sciences business and the electronic materials business.

Operating income increased to ¥229.7 billion (up 38.8 % year-over-year). Consolidated income before income taxes amounted to ¥260.4 billion (up 10.4% year-over-year) and consolidated net income attributable to FUJIFILM Holdings totaled ¥211.2 billion (up 16.5% year-over-year). The effective currency exchange rates for the U.S. dollar and the euro against the yen during this fiscal year were ¥113 and ¥131, respectively.

Revenue by Operating Segment

Amount Unit: Billions of yen

Segment	Year ended March 31, 2022		Year ended March 31, 2021		Change (Amount)	Change (%)
	From April 1, 2021 to March 31, 2022	From April 1, 2021 to March 31, 2022	From April 1, 2020 to March 31, 2021	From April 1, 2020 to March 31, 2021		
Healthcare		801.7		579.4	222.3	38.4%
Materials		627.2		566.2	61.0	10.8%
Business Innovation		763.5		761.7	1.8	0.2%
Imaging		333.4		285.2	48.2	16.9%
Consolidated Total		2,525.8		2,192.5	333.3	15.2%

Operating Income by Operating Segment

Amount Unit: Billions of yen

Segment	Year ended March 31, 2022 From April 1, 2021 to March 31, 2022	Year ended March 31, 2021 From April 1, 2020 to March 31, 2021	Change (Amount)	Change (%)
Healthcare	100.5	56.4	44.1	78.4%
Materials	68.4	51.3	17.1	33.2%
Business Innovation	57.9	73.1	(15.2)	(20.8%)
Imaging	37.0	15.6	21.4	137.2%
Corporate Expenses and Eliminations	(34.1)	(30.9)	(3.2)	—
Consolidated Total	229.7	165.5	64.2	38.8%

Healthcare Segment

In the Healthcare segment, consolidated revenue amounted to ¥801.7 billion (up 38.4*% year-over-year).

Consolidated operating income amounted to ¥100.5 billion (up 78.4% year-over-year).

In the medical systems business, revenue surged due to the growth in demand for products which are useful for COVID-19-related tests and higher sales of products in the medical IT, endoscope, IVD and other fields. Another factor contributing to strong business performance is the steady creation of group synergy with FUJIFILM Healthcare Corporation, a new group company which launched operations on March 31, 2021 after acquiring the diagnostic imaging-related business from Hitachi, Ltd. In the X-ray imaging diagnostics field, in addition to tapping into growing demand related to COVID-19 in Japan, sales of mammography DR were strong reflecting a recovery in demand for medical examinations. Higher sales of the x-ray imaging diagnostics system *FCR* (Fuji Computed Radiography), mainly in emerging countries, also contributed to a rise in overall revenue. In the ultrasound diagnostics field, sales of the ultrasound diagnostic device *Sonosite PX* for point-of-care (POC) use and the stationary ultrasound diagnostic device *ARIETTA 750* increased mainly in the U.S. and Europe. In February 2022, *Sonosite LX*, the highest-end model for POC use, was released in the U.S. and Australia. In the medical IT field, sales of systems and services, in particular *SYNAPSE*, the Picture Archiving and Communication System (PACS), and *SYNAPSE VINCENT*, the 3D image analysis system, were strong mainly in Japan, China and Europe. As part of our efforts to enhance diagnostic support functions using AI technology, we released *CXR-AID*, a software for detecting lesions in chest x-ray images, which supports the diagnosis of lung cancer, pneumonia and pneumothorax through plain chest x-ray images, in August 2021. In the endoscopes field, sales of such products as the *7000 System*, which allows special-light observation, rose significantly mainly in the U.S. and Europe. In the In-Vitro Diagnostics (IVD) field, revenue surged due to solid sales of *FUJI DRI-CHEM* (blood biochemical test) equipment and slides, FUJIFILM Wako Pure Chemical Corporation's biochemical reagents and COVID-19-related testing equipment and reagents. In the CT/MRI field, revenue rose as we promoted sales of FUJIFILM Healthcare Corporation's products, which have been newly added to the product line-up, by using FUJIFILM Corporation's sales channels, and demand related to COVID-19 increased.

In the bio CDMO business, revenue soared, driven by steady progress of contract process development and manufacturing of biopharmaceuticals in Europe and the U.S. To further accelerate business growth, a decision was taken in June 2021 to make investments totaling approximately ¥90.0 billion in manufacturing facilities to increase production capacity of gene therapy drugs and vaccine substances at U.S. sites and production capacity of antibody drugs and gene therapy substances at UK sites. Operation of the expanded facilities is scheduled to start in the latter half of 2023.

In the life sciences business, revenue rose significantly due to strong sales of cell culture media for biopharmaceutical production by FUJIFILM Irvine Scientific, Inc. (based in the U.S.), among other products. In December 2021, we launched operations at a new manufacturing facility in the Netherlands to increase production capacity of cell culture media, following which a global production system that provides stronger support for our customers' drug discovery / pharmaceutical manufacturing became available in Japan, the U.S. and Europe. In

March 2022, we acquired Shenandoah Biotechnology, Inc., a U.S. biotech firm that develops, manufactures and sells cytokines that promote cell proliferation, differentiation and signaling. With this acquisition, we will further strengthen R&D and proposals for cell culture-related products that combine cell culture media and cytokines, etc., and expand the R&D / manufacturing support business for cell therapy drugs, which is a rapidly growing market.

In the pharmaceutical business, revenue decreased because of a drop in demand in the market for antibacterial agents. On March 28, 2022, as part of business portfolio optimization in the life sciences field, FUJIFILM Toyama Chemical Co., Ltd.'s radiopharmaceutical business was transferred to PeptiDream Inc. While continuing development of the existing pipeline, we plan to focus on contract businesses, in particular contract process development / manufacturing of nucleic acid drugs and mRNA vaccines, including next-generation COVID-19 vaccine candidates, as well as manufacturing, sales and contract manufacturing of penicillin and other antibacterial agents.

In the consumer healthcare business, in addition to higher sales of *MetabARRIER EX* and other supplements, favorable sales of *ASTALIFT Opme*, the first product from the *ASTALIFT Opme* Series which features effective skin care through simple steps, contributed to revenue increase. In February 2022, we released a new food with functional claims *MetabARRIER Kuzunohana Isoflavone EX*, and in March, we launched a new version of *ASTALIFT Whiteshield Supplement*, which is a food with functional claims from the *ASTALIFT* brand's inner care series. Also in March, we released new products from a new skincare brand *cresc. by ASTALIFT* which targets young people with dry and sensitive skin. We will continue to provide unique products that cater to customer needs and contribute to people's beauty and health.

Materials Segment

In the Materials segment, consolidated revenue amounted to ¥627.2 billion (up 10.8% year-over-year).

Consolidated operating income amounted to ¥68.4 billion (up 33.2% year-over-year).

In the electronic materials business, revenue soared as sales of a wide range of products, including photo resist, CMP slurries, post CMP cleaner and polyimide, rose in line with the brisk demand for semiconductors. We will continue to accelerate growth by providing a wide range of products for miniaturized and highly integrated semiconductor devices, including those for cutting-edge semiconductors for use in 5G and self-driving cars.

In the display materials business, although sales of *WV (Wide View) Film* dropped due to a decline in demand, overall revenue was flat year-over-year, covered by firm sales of advanced materials for TVs and IT-related products, which are in line with an increasing demand for remote work, continuing from the previous fiscal year.

In the industrial products business, a recovery in sales of non-destructive inspection equipment / materials to the airline industry in Europe and the U.S, which had been hit by the COVID-19 pandemic, contributed to a rise in revenue.

In the fine chemicals business, a recovery in sales of reagents in line with the resumption of R&D activities at universities and companies and higher sales of polymerization materials and other chemical products drove revenue higher.

In the recording media business, revenue climbed as demand for data archiving tapes, which had fallen amid the COVID-19 pandemic, began to trend upward. In September 2021, we launched *FUJIFILM LTO Ultrium9 Data Cartridge* compatible with the ninth generation LTO Ultrium magnetic tape storage media standard, which is optimal for backing up and archiving large-capacity data. In addition to safe, low-cost and long-term storage of large-capacity data, magnetic tape is attracting attention as it significantly reduces environmental load by mitigating the amount of CO₂ emissions from electricity consumption during data storage by 95%*1 compared to hard disk drives. We will continue to expand the business by developing and offering high-performance / high-quality media and services that meet the needs of our customers, and work to resolve social issues.

*1: Using magnetic tape for saving 100PB of data for 10 years generates 95% less CO₂ emissions (approximately 2,400 tons) during data storage than when using HDD. (Source: Brad Johns Consulting, LLC "Improving Information Technology Sustainability with Modern Tape Storage")

In the graphic communication business, the resumption of economic activity led to an upturn in printing demand, which had been hit by the COVID-19 pandemic, as a result of which sales in the printing plates field and the digital printing field rose, boosting overall revenue. In the printing plates field, the *ZX*, a processless CTP plate which does not require developing chemicals yet delivers performance on par with processed CTP plates, was launched

overseas in September 2021. In the digital printing field, we launched *Jet Press 750S High Speed Model*, the world's fastest*2 B2 sheet-fed digital inkjet press with output speeds of 5,400 sheets per hour, in November 2021. In the production-related field, we released *Revoria Press PC1120*, a high-end production color printer under the new *Revoria* brand, in July 2021. We will further expand business by developing / delivering innovative products that utilize our advanced proprietary technology.

*2: According to a survey by Fujifilm as of March 2022

In the inkjet business, sales of industrial inkjet printheads were steady, reflecting the growing demand in the construction material printing markets in Europe and China. Regarding ink sales, sales of mainly dye inks for household and office markets rose, contributing to overall revenue growth. In March 2022, we announced the construction of a new manufacturing plant in the U.S. for colorants used for water-based pigment inkjet inks, in anticipation of growing demand for inkjet printing. We will accelerate business growth further by building a global manufacturing structure that satisfies the needs of the inkjet market.

Business Innovation Segment

In the Business Innovation segment, consolidated revenue amounted to ¥763.5 billion (up 0.2% year-over-year).

Consolidated operating income amounted to ¥57.9 billion (down 20.8% year-over-year).

In the office solutions business, the partial shutdown of factories in China resulting from the lockdown, tight supply of semiconductors and other parts, and logistics disruptions caused delays in equipment supply / installation, but revenue remained at the same level as in the previous year due to the effects of foreign exchange rates and a recovery in non-hardware sales from the impact of the COVID-19 pandemic. In April 2021, we released a new model of *Apeos*, a digital color multifunction device / printer with a totally new design under the FUJIFILM brand and stronger security features. In February 2022, we expanded the lineup of this product. We are expanding our business globally and started selling office products in new markets in the third quarter as part of our efforts to utilize FUJIFILM Corporation's overseas sites and major sales agencies. We will continue to accelerate global expansion including new OEM supply partnerships.

In the business solutions business, revenue climbed due to such factors as an increase in business with Japan municipal governments and steady performance by the BPO (Business Process Outsourcing) business mainly overseas. In January 2022, the acquisition of HOYA Digital Solutions Corporation was completed, and business operations started as FUJIFILM Digital Solutions Co., Ltd. on the same day. We will further accelerate growth for business solutions by continuing to offer new solutions and services to support customers' digital transformation (DX), including marketing and implementation support of ERP (enterprise resource planning) systems provided by the new company.

Imaging Segment

In the Imaging segment, consolidated revenue amounted to ¥333.4 billion (up 16.9% year-over-year).

Consolidated operating income amounted to ¥37.0 billion (up 137.2% year-over-year).

In the consumer imaging field, steady sales of instant photo systems, color paper and dry minilabs / materials drove revenue higher. Regarding instant photo systems, sales of both devices and film fared well. In October 2021, we launched the *instax Link WIDE* smartphone printer, which can print images taken with a smartphone on to a wide-format film, twice the size of the regular card-sized mini-format film. Due to a newly added function, which generates a QR code for a voice / text messages, location data, a website's URL, etc. and incorporates it into a print, *instax Link WIDE* has been well received not only for personal use but also for business use. In December 2021, we launched the hybrid instant camera *instax mini Evo*, a flagship model of the *instax* series, which supports mini-format film. Sales volume rose strongly as it gained a high reputation for its classical design and 100 combinations of shooting effects. We will continue meeting increasingly diverse customer needs and offering user-friendly, high-value added products and services, while also communicating to the world the intrinsic photographic values of "shooting, preserving, displaying, and gifting."

In the professional imaging field, revenue increased as sales of digital cameras and broadcast and cinema lenses fared well. Regarding digital cameras, sales rose for the large-format mirrorless digital camera *FUJIFILM GFX100S* with a high resolution of 102 million pixels. In September 2021, the *FUJIFILM GFX50S II* large-format mirrorless digital camera equipped with a 51.4-million-pixel image sensor was released as the latest addition to the

GFX Series, which resulted in the *GFX* user base expanding. In November 2021, we launched the *FUJIFILM X-T30 II* mirrorless digital camera, the latest model of the *X* Series, which delivers premium image quality despite being compact and lightweight. We will continue to offer attractive products by realizing the highest image quality through the *GFX* Series and the best balance between image quality and size through the *X* Series. Sales of broadcast and cinema lenses were higher than in the previous year, due to a recovery in demand, which had been hit by the COVID-19 pandemic.

Outlook for the Fiscal Year ending March 31, 2023

Amount Unit: Billions of yen

	Outlook for the Fiscal Year ending March 31, 2023	Actual results for the Fiscal Year ending March 31, 2022	Change (% / Amount)
Revenue	2,650.0	2,525.8	4.9%
Operating income	245.0	229.7	6.7%
Income before income taxes	255.0	260.4	(2.1%)
Net income attributable to FUJIFILM Holdings	192.0	211.2	(9.1%)
ROE (%)	7.6	9.0	(1.4 points)
ROIC (%)	5.7	5.6	0.1 points
Exchange rates (Yen / US\$)	¥120	¥113	¥7
Exchange rates (Yen / Euro)	¥132	¥131	¥1

Regarding the consolidated performance forecast for the fiscal year ending March 31, 2023, FUJIFILM Holdings (the Company) projects ¥2,650.0 billion in revenue (up 4.9% year-over-year), ¥245.0 billion in operating income (up 6.7% year-over-year), ¥255.0 billion in income before income taxes (down 2.1% year-over-year) and ¥192.0 billion in net income attributable to FUJIFILM Holdings per share (down 9.1% year-over-year), based on such factors as business growth centered on healthcare and advanced materials, profitability improvement in all businesses, and the effects of foreign exchange rates.

The projected currency exchange rates for the U.S. dollar and the euro against the yen during the fiscal year ending March 31, 2023, are ¥120 and ¥132, respectively.

(2) Analysis of Consolidated Financial Position (Assets, Liabilities, Shareholders' Equity and Cash Flows)

At the end of the fiscal year ended March 31, 2022, total assets increased by ¥406.1 billion year-over-year to ¥3,955.3 billion, due to an increase in tangible fixed assets. Total liabilities increased by ¥103.4 billion to ¥1,430.4 billion. FUJIFILM Holdings shareholders' equity increased by ¥298.1 billion year-over-year to ¥2,502.7 billion. As a result, the current ratio decreased by 34.3 percentage points, to 176.1%, the debt-equity ratio decreased by 3.0 percentage points, to 57.2%, and the equity ratio increased by 1.2 percentage points year-over-year, to 63.3%. The Company is maintaining a stable level of asset liquidity and a sound capital structure.

During the fiscal year ended March 31, 2022, net cash provided by operating activities totaled ¥323.9 billion, due to a decrease in accounts receivable, and depreciation and amortization. Net cash used in investing activities amounted to ¥153.5 billion, due to the acquisition of property, plant, equipment and other factors. Thus, free cash flow, or the sum of cash flow from operating and investing activities, increased by ¥28.9 billion year-over-year to ¥170.4 billion. Net cash used in financing activities amounted to ¥105.2 billion, due to a decrease in debts and other factors. As a result, cash and cash equivalents at the end of the fiscal year under review amounted to ¥486.3 billion, up ¥91.5 billion compared to the end of last fiscal year (March 31, 2021).

(Reference) Cash Flow Related Indices (Consolidated)

	Year ended March 31, 2022 From April 1, 2021 to March 31, 2022	Year ended March 31, 2021 From April 1, 2020 to March 31, 2021
Ratio of shareholders' equity to total assets (%)	63.3	62.1
Ratio of market capitalization to total assets (%)	76.0	74.0
Ratio of interest-bearing debt to operating cash flow (years)	1.4	1.2
Interest coverage ratio (times)	139.9	163.3

Ratio of shareholders' equity to total assets	: Shareholders' equity / Total assets
Ratio of market capitalization to total assets	: Market capitalization (Year-end closing price x No. of shares outstanding at year-end*) / Total assets *Excluding treasury shares
Ratio of interest-bearing debts to operating cash flow	: Interest-bearing debts (corporate bond securities and short- and long-term debts) / Operating cash flow
Interest coverage ratio	: Operating cash flow / interest paid

(3) Basic Policy Regarding Distribution of Profits and Dividends Applicable to the Fiscal Year under Review and Subsequent Fiscal Year

In addition to reflecting consolidated performance trends, dividend levels are to be determined based on the consideration of such factors as the level of funds required for M&A transactions, capital investment and R&D investments needed to support priority business expansion, as well as other measures aimed at increasing the Company's corporate value in the future. Adequate buybacks will be undertaken considering the situation of cash flows and stock prices. The Company has the policy of shareholder returns that put emphasis on cash dividends, setting the targeted dividend payout ratio of 30%.

The Company plans to disburse a year-end cash dividend of ¥55.0 per share. As interim cash dividend of ¥55.0 per share has already been disbursed, cash dividend applicable to the fiscal year under review is expected to total ¥110.0 per share.

As for dividends for the fiscal year ending March 31, 2023, the Company plans to disburse an interim dividend of ¥60.0 per share and a year-end dividend of ¥60.0 per share, making a year total of ¥120.0 per share.

2. CORPORATE STRUCTURE OF FUJIFILM GROUP

The disclosure is omitted since there are no significant changes in the business and group organizational structure from the latest Annual Securities Report filed on June 30, 2021.

3. CORPORATE DIRECTION

Using leading-edge, proprietary technologies to provide top-quality products and services, the Fujifilm Group aims to "resolve social issues through our business activities" and contribute to the realization of a sustainable society.

In August 2017, the Group drew up the long-term CSR plan "Sustainable Value Plan 2030" (hereafter SVP2030). The medium-term management plan VISION2023 announced on April 15, 2021 was positioned as a specific action plan for achieving the goals set in the SVP2030, and we have been working to resolve social issues by creating "new values" through our business activities.

VISION2023 calls for addressing issues in Environment, Health, Daily Life and Work Style through business activities, and "accelerating growth in healthcare and advanced materials and building a more resilient business platform to facilitate sustainable growth." Under this vision, we will strengthen our business portfolio management and cash flow management to secure growth investment capital and accelerate and strengthen the cycle of intensive investment of management resources in new / future potential as well as priority businesses.

In FY2021, the first year of the medium-term management plan, we achieved record-high operating income, net income before income taxes and net income attributable to FUJIFILM Holdings, making a good start toward achieving ¥2.7 trillion in revenue and ¥260.0 billion in operating income in FY2023 as set in VISION2023.

In FY2022, with the widespread rollout of COVID-19 vaccines and other factors, it is expected that a growing number of countries will attempt to live with COVID-19. Meanwhile, there are concerns about global stagflation (inflation in a recessionary phase) impacting the world economy, attributable to supply chain disruptions and soaring prices of energy products and metals, including crude oil, natural gas and aluminum, due to the Russia-Ukraine crisis, as well as a shortage of semiconductors and disruptions in international logistics. Under these circumstances, the Group will strive to improve profitability of all businesses and promote stable cash generation. Realizing the primary goals of “accelerating business growth in healthcare and advanced materials, and building a more resilient business platform to facilitate sustainable growth” will allow us to reinforce our business portfolio and overcome these difficulties.

Growth Strategy in the Healthcare Segment

In the Healthcare segment, the medical systems business will drive sales growth to ensure increases in revenue and profit. In the life sciences field, we will position the bio CDMO business, which is expected to grow significantly in the medium to long term, as a priority business and aim to expand business by offering end-to-end values as a company supporting state-of-the-art therapeutic drug discovery. Also, with the aim of contributing to COVID-19 pandemic control, we will supply portable digital x-rays, diagnostic ultrasounds and other medical equipment, and undertake contract process development and manufacturing of vaccines, etc. for pharmaceutical companies.

In the medical systems business, we will pursue various synergy effects through intra-group reorganization and cross-selling with FUJIFILM Healthcare Corporation. In April 2022, we announced the release of the 3D image analysis system *SYNAPSE VINCENT Core* (for CT/MRI) this summer, which is the first synergy product development with FUJIFILM Healthcare Corporation. In the medical IT field, we will promote the development and practical application of AI technology that supports the workflow at the medical frontline under the *REiLI* brand. In June 2022, *SYNAPSE VINCENT Cloud* will be released, which is a cloud-based service for using applications for the 3D image analysis system *SYNAPSE VINCENT*. We also plan to launch *SYNAPSE Creative Space* by the end of this year. This is a cloud service that allows physicians and researchers without expertise in programming to develop AI technology for assisting diagnostic imaging by using an AI R&D infrastructure platform developed jointly with the National Cancer Center in Japan. We will further expand the AI/IT solution business, which combines these IT systems equipped with the latest AI technology with a wide range of modalities such as CT, MRI, X-ray diagnostic systems, mammography, ultrasound, endoscopy, etc.

In the bio CDMO business, we will expand the business at a higher rate than that of the growing biopharmaceutical market by building a one-site, one-stop system at our existing sites in the U.S. and Europe, which account for a large share of the biopharmaceutical market. The system is aimed at performing small lots to mass contract production, covering everything from contract process development to formulation/packaging of various biopharmaceutical products, including antibody drugs, hormone preparations, gene therapeutic drugs and vaccines. In April 2022, we acquired a cell therapy manufacturing facility from U.S. bio-venture Atara Biotherapeutics, Inc., which started operations as the California site of FUJIFILM FUJIFILM Diosynth Biotechnologies, a world’s leading bio CDMO company. This will also allow us to roll out our contract business for cell therapy drugs, including gene-modified cell therapeutics.

In the life sciences business, four group companies— FUJIFILM Cellular Dynamic, Inc., FUJIFILM Irvine Scientific, Inc., FUJIFILM Wako Pure Chemical Corporation and Shenandoah Biotechnology, Inc. acquired in March 2022—will cooperate to provide end-to-end solutions to customers through global supply and sales of cells, culture media and reagents, including human iPS for drug discovery support, as a set product. In the field of cell therapeutics utilizing iPS cell technology / know-how, we will accelerate development of cell therapeutics with

alliance partners and promote contract the development / manufacturing business.

In February 2022, we launched LS-CVC, a corporate venture capital in the life sciences field. LS-CVC has an investment capacity up to ¥7.0 billion over a 5-year period until 2026, targeting bio ventures around the world with cutting-edge technologies, etc. In collaboration with FUJIFILM Life Science Strategic Business Office (U.S.) and FUJIFILM Life Science Strategic Business Office Europe (Europe), which are the business strategy centers that lead collaborations with academia and companies, the Life Sciences Strategy Headquarters, which develops and promotes overall cross-business strategies, will play a central role in approaching bio ventures with cutting-edge technologies / know-how and innovative business models to further strengthen existing business and create new ones.

In the pharmaceutical business, we will develop the process development / contract manufacturing business for next-generation nucleic acid drugs and mRNA vaccines by using our lipid nanoparticulate (LNP) manufacturing facilities and leveraging our proprietary nano-dispersion, analysis and process technologies.

[Growth Strategy in the Materials Segment]

In the Materials segment, we established the Advanced Materials Strategy Headquarters in October 2021 to expand the advanced materials business through cross-divisional strategy management and business portfolio establishment on a customer application basis, in addition to new business development over the medium to long term.

In the electronic materials business, the wider use of AI, IoT and 5G and acceleration of DX will increase demand for semiconductors, and processing capacity, miniaturization and integration required for higher performance of semiconductors are expected to advance. To meet such market needs, we will continue to implement timely capital expenditure for the development and stable supply of materials that enable advanced performance. We will also accelerate business growth by developing various new semiconductor process materials, including resists for advanced fields, to widen the lineup and provide customers with a full range of products.

In the display materials business, in addition to maintaining our strong market position of TAC products for LCD panels, we will utilize our thin film and multilayer-coating technologies to develop and launch differentiated products with the aim of maintaining a strong market share of organic EL materials and diversifying the material business for new applications, such as in-vehicle displays.

In the industrial products business, we will continue to expand sales of *EXCLEAR*, a sensor film for touch panels, and other advanced products utilizing our proprietary technologies, while expanding the business by aggressively branching into new fields such as optical sensors and communications-related materials.

In the fine chemical business, we will expand business by focusing on the life sciences, electronics and environment / energy fields with high growth potential, and developing high quality products based on our proprietary “flow synthesis” and other innovative manufacturing process technologies.

In the graphic communication business, FUJIFILM Corporation’s Graphic Systems Business Division and FUJIFILM Business Innovation Corp.’s Graphic Communication Services Business Group were integrated as the Graphic Communication Division in July 2021 to accelerate creation of synergy within the Group and provide further value to our customers globally. Focusing primarily on commercial printing and packaging printing, in FY2022, we will expand sales of digital print systems (Print On Demand) worldwide and accelerate the launch of various DX solutions for brand owners and printing companies by combining FUJIFILM Corporation’s global customer base with FUJIFILM Business Innovation Corp.’s sales force and technology / product competitiveness.

[Growth Strategy in the Business Innovation Segment]

In the Business Innovation segment, FUJIFILM Business Innovation Corp. will promote expansion of new FUJIFILM brand products and their global sales growth. In addition, we will accelerate continuous growth and business portfolio transformation by expanding sales of DX solution services and developing DX strategies for the BPO business. Specifically, we will contribute to client companies' DX by utilizing the customer base at the office solutions business to tap into remote work demand and provide solutions and services useful for document

management; by enhancing value with a focus on stronger IT / security services for small and midsize companies; by expanding digital business process services based on document digitalization / processing by FUJIFILM RIPCORDER G.K.; and by marketing and implementation support of ERP (enterprise resource planning) systems, mainly Microsoft Dynamics 365 through FUJIFILM Digital Solutions Co., Ltd.

Growth Strategy in the Imaging Segment

In the Imaging segment, we will expand the imaging business through such measures as launching attractive new instant photo systems and mirrorless digital cameras, revitalizing photo printing demand through the "Print Days" campaign to highlight the value of photo prints, exploring further sales opportunities of FUJIFILM Business Innovation Corp.'s printers, and advancing into new B to B fields, including projectors and surveillance cameras. We will also develop products that connect digital cameras and prints, a video / photo content business, an imaging media / image processing solution business and other new commercial services.

Initiatives in Priority Areas Under SVP2030

From the perspective of "resolving social issues through our business activities" and "considering society and the environment in our business processes," we are striving to achieve goals set out for four priority areas in SVP2030, namely Environment, Health, Daily Life, and Work Style, as well as Supply Chain and Governance which serve as the basis of our business activities. In Environment, we are actively addressing the reduction of CO₂ emissions in response to climate change, which is a pivotal issue common to the international community. In December 2021, our new CO₂ emissions reduction target was announced. Under the new target, we will aim to achieve net-zero CO₂ emissions from energy consumed in-house by FY2040. Plans are also to achieve a 50% reduction in CO₂ emissions (compared to FY2019 levels) by FY2030 across the entire product cycle from material procurement, manufacturing, and transportation, to use and disposal of our products. This target is in line with the 1.5 degrees Celsius goal of the Paris Agreement, based on which we established the "Green Value Climate Strategy" as our new environmental strategy. The main points of this strategy are production activities with low environmental impact which is called "Green Value Manufacturing" and creation and dissemination of products / services with excellent environmental performance which are called "Green Value Products." Based on this strategy, FUJIFILM Corporation, Tokyo Gas Co., Ltd. and Minamiashigara City signed a comprehensive partnership agreement towards a decarbonized future on March 29, 2022. Based on this agreement, we will aim at creating a carbon neutral model in manufacturing.

In Health, our goal is to increase the number of countries where we introduce our medical AI-based products / services, from 70 as of FY2021, to all 196 countries and regions by FY2030. Furthermore, in April 2022, we issued a ¥120 billion social bond offering (social impact bond), the largest in the Japanese corporate bond market*, as a means to raise funds for the bio CDMO business, which contributes to fulfilling unmet medical needs and improving access to medicine. This will allow us to support client pharmaceutical companies through a stable supply of high-quality biopharmaceuticals and contribute to resolving social issues, such as response to unmet medical needs and easier access to medicine. In addition, we are strongly promoting health and productivity management by positioning the maintenance and improvement of employees' health as a management issue that serves as the basis for implementing our corporate philosophy and vision. In recognition of such initiatives, we have been selected as a Health & Productivity Stock for the second consecutive year in a program run by the Ministry of Economy, Trade and Industry and the Tokyo Stock Exchange. We will continue with our initiatives in resolving social issues through healthcare businesses and contribute to the establishment of a healthy society with longevity.

In Work Style, we will offer 50 million people work styles that help workers improve productivity and demonstrate creativity by providing solutions and services that spur business innovation.

In Governance, we have positioned corporate governance as an important management issue and are addressing enhancement of it. Through sincere and fair business activities, we aim to contribute to the sustainable

development of society, while achieving sustainable growth of the Group and improving its corporate value.

*According to a survey by Fujifilm as of March 2022

FY2022 Fujifilm Group Corporate Direction

The Group's Corporate Direction for FY2022 is "NEVER STOP Taking on Challenges, United as All-Fujifilm! Enhance our 'earning power' by providing innovative products and services that help solve society's greatest challenges." For the creation and expansion of new markets, we will promote development and supply of products and services with new values by accurately grasping market needs. Viewing the resolution of social issues as an opportunity for business growth, we will contribute to the development of a sustainable society by taking on the challenge as "All-Fujifilm," bringing together the power of all companies, organizations, and employees under the umbrella of FUJIFILM Holdings with the NEVER STOP spirit.

4. BASIC RATIONALE FOR SELECTION OF ACCOUNTING STANDARDS

Due to the agreement related to the Eurodollar convertible bond issuance in 1970, the Group has prepared and disclosed its consolidated financial statements in accordance with accounting principles generally accepted in the U.S.

The Company is considering the adaption of IFRS through addressing internal and external factors that affect both within and outside of Japan.

5. CONSOLIDATED FINANCIAL STATEMENTS

FUJIFILM Holdings Corporation (4901)

(1) Consolidated Balance Sheets

Amount Unit: Millions of yen

	As of March 31, 2022	As of March 31, 2021	Change
ASSETS			
Current assets:			
Cash and cash equivalents	486,328	394,795	91,533
Notes and accounts receivable:			
Trade and finance	570,851	574,319	(3,468)
Lease receivable	45,573	51,644	(6,071)
Affiliated companies	2,354	2,462	(108)
Allowance for doubtful receivables	(20,144)	(22,707)	2,563
	598,634	605,718	(7,084)
Inventories	504,467	417,662	86,805
Prepaid expenses and Other	135,300	89,201	46,099
Total current assets	1,724,729	1,507,376	217,353
Investments and long-term receivables:			
Investments in and advances to affiliated companies	43,467	31,849	11,618
Investment securities	105,329	111,650	(6,321)
Long-term lease receivables	60,298	62,068	(1,770)
Other long-term receivables	24,963	25,426	(463)
Allowance for doubtful receivables	(3,010)	(3,167)	157
Total investments and long-term receivables	231,047	227,826	3,221
Property, plant and equipment:			
Land	104,718	105,764	(1,046)
Buildings	739,525	718,513	21,012
Machinery and equipment	1,497,457	1,474,840	22,617
Construction in progress	145,084	63,913	81,171
	2,486,784	2,363,030	123,754
Less accumulated depreciation	(1,749,945)	(1,727,779)	(22,166)
Total property, plant and equipment	736,839	635,251	101,588
Other assets:			
Operating lease right-of-use assets	83,389	78,203	5,186
Goodwill, net	824,003	804,199	19,804
Other intangible assets, net	152,691	128,496	24,195
Deferred income taxes	24,210	33,179	(8,969)
Other	178,372	134,673	43,699
Total other assets	1,262,665	1,178,750	83,915
Total assets	3,955,280	3,549,203	406,077

	As of March 31, 2022	As of March 31, 2021	Change
LIABILITIES			
Current liabilities:			
Short-term debt	200,095	63,729	136,366
Notes and accounts payable:			
Trade	249,919	217,308	32,611
Construction	51,868	21,157	30,711
Affiliated companies	1,396	1,455	(59)
	303,183	239,920	63,263
Accrued income taxes	21,453	24,527	(3,074)
Accrued liabilities	226,830	197,519	29,311
Short-term operating lease liabilities	31,494	28,938	2,556
Other current liabilities	196,520	161,651	34,869
Total current liabilities	979,575	716,284	263,291
Long-term liabilities:			
Long-term debt	247,101	439,351	(192,250)
Accrued pension and severance costs	27,927	30,090	(2,163)
Long-term operating lease liabilities	56,866	54,946	1,920
Deferred income taxes	54,035	32,240	21,795
Other long-term liabilities	64,836	54,135	10,701
Total long-term liabilities	450,765	610,762	(159,997)
Total liabilities	1,430,340	1,327,046	103,294
EQUITY			
FUJIFILM Holdings shareholders' equity			
Capital	40,363	40,363	-
Common stock, without par value:			
Authorized: 800,000,000 shares			
Issued: 514,625,728 shares			
Retained earnings	2,867,848	2,702,760	165,088
Accumulated other comprehensive income (loss)	75,993	(52,836)	128,829
Treasury stock, at cost			
As of March 31, 2021: 114,823,247 shares			
As of March 31, 2022: 113,834,546 shares	(481,547)	(485,721)	4,174
Total FUJIFILM Holdings shareholders' equity	2,502,657	2,204,566	298,091
Noncontrolling interests	22,283	17,591	4,692
Total equity	2,524,940	2,222,157	302,783
Total liabilities and equity	3,955,280	3,549,203	406,077

Note: Details of accumulated other comprehensive income (loss)

	As of March 31, 2022	As of March 31, 2021	Change
Unrealized gains (losses) on securities	27	1	26
Foreign currency translation adjustments	148,700	32,973	115,727
Pension liability adjustments	(72,780)	(86,038)	13,258
Unrealized gains (losses) on derivatives	46	228	(182)

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income**(Consolidated Statements of Income)****Year ended March 31**

Amount Unit: Millions of yen

	Year ended March 31, 2022 From April 1, 2021 to March 31, 2022		Year ended March 31, 2021 From April 1, 2020 to March 31, 2021		Change	
					Amount	%
	%		%			
Revenue:	100.0	2,525,773	100.0	2,192,519	333,254	15.2
Cost of sales:	59.1	1,492,549	60.3	1,322,828	169,721	12.8
Gross profit	40.9	1,033,224	39.7	869,691	163,533	18.8
Operating expenses:						
Selling, general and administrative	25.8	652,995	25.3	552,068	100,927	18.3
Research and development	6.0	150,527	6.9	152,150	(1,623)	(1.1)
Operating income	31.8	803,522	32.2	704,218	99,304	14.1
	9.1	229,702	7.5	165,473	64,229	38.8
Other income (expenses):						
Interest and dividend income		4,646		3,884	762	
Interest expense		(2,316)		(2,578)	262	
Foreign exchange gains (losses), net		4,437		(2,593)	7,030	
Gains (losses) on equity securities, net		4,453		48,778	(44,325)	
Other, net		19,524		22,906	(3,382)	
Income before income taxes	1.2	30,744	3.3	70,397	(39,653)	(56.3)
	10.3	260,446	10.8	235,870	24,576	10.4
Income taxes						
Current		48,615		47,973	642	
Deferred		8,514		7,638	876	
	2.3	57,129	2.5	55,611	1,518	2.7
Equity in net earnings (losses) of affiliated companies	0.6	13,128	0.1	3,198	9,930	310.5
Net income	8.6	216,445	8.4	183,457	32,988	18.0
Less: Net (income) loss attributable to the noncontrolling interests	(0.2)	(5,265)	(0.1)	(2,252)	(3,013)	133.8
Net income attributable to FUJIFILM Holdings	8.4	211,180	8.3	181,205	29,975	16.5

Three months ended March 31

Amount Unit: Millions of yen

	Three months ended March 31, 2022 From January 1, 2022 to March 31, 2022		Three months ended March 31, 2021 From January 1, 2021 to March 31, 2021		Change	
					Amount	%
	%		%			
Revenue:	100.0	664,871	100.0	619,085	45,786	7.4
Cost of sales:	62.6	416,146	64.7	400,333	15,813	3.9
Gross profit	37.4	248,725	35.3	218,752	29,973	13.7
Operating expenses:						
Selling, general and administrative	25.1	166,890	21.3	132,346	34,544	26.1
Research and development	5.8	38,586	6.7	41,401	(2,815)	(6.8)
Operating income	30.8	205,476	28.0	173,747	31,729	18.3
Operating income	6.5	43,249	7.3	45,005	(1,756)	(3.9)
Other income (expenses):						
Interest and dividend income		605		538	67	
Interest expense		(653)		(568)	(85)	
Foreign exchange gains (losses), net		3,966		3,066	900	
Gains (losses) on equity securities, net		(1,421)		9,008	(10,429)	
Other, net		7,460		4,000	3,460	
Income before income taxes	1.5	9,957	2.6	16,044	(6,087)	(37.9)
Income before income taxes	8.0	53,206	9.9	61,049	(7,843)	(12.8)
Income taxes	0.0	7	1.5	9,416	(9,409)	(99.9)
Equity in net earnings (losses) of affiliated companies	0.4	2,798	0.6	4,039	(1,241)	(30.7)
Net income	8.4	55,997	9.0	55,672	325	0.6
Less: Net (income) loss attributable to the noncontrolling interests	(0.3)	(1,923)	(0.2)	(956)	(967)	101.2
Net income attributable to FUJIFILM Holdings	8.1	54,074	8.8	54,716	(642)	(1.2)

(Consolidated Statements of Comprehensive Income)**Year ended March 31**

Amount Unit: Millions of yen

	Year ended March 31, 2022 From April 1, 2021 to March 31, 2022	Year ended March 31, 2021 From April 1, 2020 to March 31, 2021	Change
Net income	216,445	183,457	32,988
Other comprehensive income (loss), net of tax:			
Unrealized gains (losses) on securities	26	12	14
Foreign currency translation adjustments	117,466	80,635	36,831
Pension liability adjustments	13,381	31,786	(18,405)
Unrealized gains (losses) on derivatives	(182)	336	(518)
Other comprehensive income (loss)	130,691	112,769	17,922
Comprehensive income (loss)	347,136	296,226	50,910
Less: Comprehensive (income) loss attributable to noncontrolling interests	(7,127)	(3,757)	(3,370)
Comprehensive income (loss) attributable to FUJIFILM Holdings	340,009	292,469	47,540

Three months ended March 31

Amount Unit: Millions of yen

	Three months ended March 31, 2022 From January 1, 2022 to March 31, 2022	Three months ended March 31, 2021 From January 1, 2021 to March 31, 2021	Change
Net income	55,997	55,672	325
Other comprehensive income (loss), net of tax:			
Unrealized gains (losses) on securities	20	29	(9)
Foreign currency translation adjustments	77,730	65,158	12,572
Pension liability adjustments	11,399	25,325	(13,926)
Unrealized gains (losses) on derivatives	(42)	166	(208)
Other comprehensive income (loss)	89,107	90,678	(1,571)
Comprehensive income (loss)	145,104	146,350	(1,246)
Less: Comprehensive (income) loss attributable to noncontrolling interests	(3,163)	(2,035)	(1,128)
Comprehensive income (loss) attributable to FUJIFILM Holdings	141,941	144,315	(2,374)

(3) Consolidated Statements of Changes in Shareholders' Equity

Amount Unit: Millions of yen

	Common stock	Additional paid-in capital	Retained earnings	Accumulated other comprehensive income (loss)	Treasury stock	FUJIFILM Holdings shareholders' equity	Noncontrolling interest	Total Equity
Balanced at April 1, 2020	40,363	-	2,563,091	(164,100)	(486,102)	1,953,252	40,505	1,993,757
Comprehensive income (loss):								
Net income			181,205			181,205	2,252	183,457
Change in net unrealized gains on securities				12		12		12
Foreign currency translation adjustments				79,174		79,174	1,461	80,635
Pension liability adjustments				31,742		31,742	44	31,786
Change in net unrealized gains on derivatives				336		336		336
Net comprehensive income						292,469	3,757	296,226
Purchases of stock for treasury					(20)	(20)		(20)
Sales of stock from treasury			(32)		401	369		369
Dividends paid to FUJIFILM Holdings shareholders			(39,979)			(39,979)		(39,979)
Dividends paid to noncontrolling interests							(1,314)	(1,314)
Stock acquisition rights		485				485		485
Transfer from retained earnings to additional paid-in capital		1,525	(1,525)			-		-
Equity transactions with noncontrolling interests and other		(2,010)				(2,010)	(25,357)	(27,367)
Balanced at March 31, 2021	40,363	-	2,702,760	(52,836)	(485,721)	2,204,566	17,591	2,222,157
Comprehensive income (loss):								
Net income			211,180			211,180	5,265	216,445
Change in net unrealized gains on securities				26		26		26
Foreign currency translation adjustments				115,727		115,727	1,739	117,466
Pension liability adjustments				13,258		13,258	123	13,381
Change in net unrealized losses on derivatives				(182)		(182)		(182)
Net comprehensive income						340,009	7,127	347,136
Purchases of stock for treasury					(32)	(32)		(32)
Sales of stock from treasury			(42)		4,206	4,164		4,164
Dividends paid to FUJIFILM Holdings shareholders			(44,086)			(44,086)		(44,086)
Dividends paid to noncontrolling interests							(783)	(783)
Stock acquisition rights		(1,922)				(1,922)		(1,922)
Transfer from retained earnings to additional paid-in capital		1,964	(1,964)			-		-
Equity transactions with noncontrolling interests and other		(42)				(42)	(1,652)	(1,694)
Balanced at March 31, 2022	40,363	-	2,867,848	75,993	(481,547)	2,502,657	22,283	2,524,940

(4) Consolidated Statements of Cash Flows

Amount Unit: Millions of yen

	Year ended March 31, 2022 From April 1, 2021 to March 31, 2022	Year ended March 31, 2021 From April 1, 2020 to March 31, 2021	Change
Operating activities			
Net income	216,445	183,457	32,988
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	132,999	123,423	9,576
(Gains) losses on equity securities	(4,453)	(48,778)	44,325
Deferred income taxes	8,514	7,638	876
Equity in net (gains) losses of affiliated companies, net of dividends received	(12,194)	(2,571)	(9,623)
Changes in operating assets and liabilities:			
Notes and accounts receivable	34,741	20,576	14,165
Inventories	(68,273)	9,215	(77,488)
Notes and accounts payable - trade	21,007	(9,713)	30,720
Changes in other current assets	(30,766)	64,071	(94,837)
Accrued income taxes and other liabilities	28,794	46,099	(17,305)
Other	(2,880)	27,444	(30,324)
Subtotal	107,489	237,404	(129,915)
Net cash provided by operating activities	323,934	420,861	(96,927)
Investing activities			
Purchases of property, plant and equipment	(126,054)	(100,063)	(25,991)
Purchases of software	(39,853)	(25,544)	(14,309)
Proceeds from sales and maturities of marketable and investment securities	15,119	26,239	(11,120)
Purchases of marketable and investment securities	(2,860)	(1,685)	(1,175)
(Increase) decrease in time deposits, net	(4,959)	(3,090)	(1,869)
Increase in investments in and advances to affiliated companies	(459)	(2,945)	2,486
Acquisitions of businesses, net of cash acquired	(10,714)	(173,515)	162,801
Proceeds from sale of businesses, net of cash and cash equivalents disposed of	24,480	-	24,480
Proceeds from sale of subsidiaries, net of cash and cash equivalents disposed of	-	14,707	(14,707)
Other	(8,242)	(13,485)	5,243
Net cash used in investing activities	(153,542)	(279,381)	125,839
Financing activities			
Proceeds from long-term debt	2,079	4,073	(1,994)
Repayments of long-term debt	(61,929)	(78,650)	16,721
Increase (decrease) in short-term debt, net	2,364	(625)	2,989
Payments of short-term debt with maturities longer than three months	-	(50,000)	50,000
Cash dividends paid to shareholders	(43,032)	(37,975)	(5,057)
Subsidiaries' cash dividends paid to noncontrolling interests	(783)	(1,314)	531
Net purchases of stock for treasury	(31)	(20)	(11)
Capital transactions with noncontrolling interests and other	(3,852)	1,418	(5,270)
Net cash used in financing activities	(105,184)	(163,093)	57,909
Effect of exchange rate changes on cash and cash equivalents	26,325	20,317	6,008
Net increase (decrease) in cash and cash equivalents	91,533	(1,296)	92,829
Cash and cash equivalents at beginning of year	394,795	396,091	(1,296)
Cash and cash equivalents at end of year	486,328	394,795	91,533

(5) Notes to Consolidated Financial Statements**Note Relating to the Going Concern Assumption**

N/A

Summary of Significant Accounting Policies**(A) Scope of consolidated subsidiaries**

Number of Subsidiaries 280

Main companies : FUJIFILM Corporation, FUJIFILM Business Innovation Corp.
FUJIFILM Business Innovation Japan Corp, and others**(B) Scope of affiliated companies**

Number of Affiliates : 31

Main companies : FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd. and others

(C) Significant Accounting Policies

Our consolidated financial statements are prepared based on corporate accounting standards generally accepted as fair and valid in the United States. The disclosure is omitted since there are no significant changes from the description in the latest Annual Securities Report (filed on June 29, 2020).

Segment Information

1. Year ended March 31

(A) Operating Segment Information

a. Revenue

Amount Unit: Millions of yen

	Year ended March 31, 2022 From April 1, 2021 to March 31, 2022		Year ended March 31, 2021 From April 1, 2020 to March 31, 2021		Change	
	%		%		Amount	%
Revenue:						
Healthcare:						
External customers	31.8	801,743	26.4	579,351	222,392	38.4
Intersegment		94		164	(70)	-
Total		801,837		579,515	222,322	38.4
Materials:						
External customers	24.8	627,118	25.8	566,226	60,892	10.8
Intersegment		1,373		1,264	109	-
Total		628,491		567,490	61,001	10.7
Business Innovation:						
External customers	30.2	763,549	34.8	761,706	1,843	0.2
Intersegment		3,846		2,440	1,406	-
Total		767,395		764,146	3,249	0.4
Imaging:						
External customers	13.2	333,363	13.0	285,236	48,127	16.9
Intersegment		2,425		1,878	547	-
Total		335,788		287,114	48,674	17.0
Eliminations		(7,738)		(5,746)	(1,992)	-
Consolidated total	100.0	2,525,773	100.0	2,192,519	333,254	15.2

b. Operating income

Amount Unit: Millions of yen

	Year ended March 31, 2022 From April 1, 2021 to March 31, 2022		Year ended March 31, 2021 From April 1, 2020 to March 31, 2021		Change	
	%		%		Amount	%
Operating Income:						
Healthcare	12.5	100,536	9.7	56,361	44,175	78.4
Materials	10.9	68,386	9.0	51,344	17,042	33.2
Business Innovation	7.5	57,914	9.6	73,086	(15,172)	(20.8)
Imaging	11.0	36,977	5.4	15,591	21,386	137.2
Total		263,813		196,382	67,431	34.3
Corporate expenses and eliminations		(34,111)		(30,909)	(3,202)	-
Consolidated total	9.1	229,702	7.5	165,473	64,229	38.8

Note: The major products and services of each operating segment are as follows:

Healthcare:	Equipment and materials for medical systems, contract development and manufacturing organization of biopharmaceuticals, iPS cells (regenerative medicine), drug discovery support such as cell culture media and reagents, pharmaceuticals, cosmetics and supplements, etc.
Materials:	Electronic materials, display materials, industrial equipment, fine chemicals, recording media, equipment and materials for graphic communication, inks and industrial inkjet printheads, etc.
Business Innovation:	Digital MFPs, solutions and services, etc.
Imaging:	Instant photo systems, color films, services and equipment for photofinishing, digital cameras and optical devices, etc.

Total Assets

Amount Unit: Millions of yen

	As of March 31, 2022	As of March 31, 2021	Change	
			Amount	%
Total assets:				
Healthcare	1,439,651	1,290,127	149,524	11.6
Materials	1,067,932	929,883	138,049	14.8
Business Innovation	921,719	892,515	29,204	3.3
Imaging	287,269	278,274	8,995	3.2
Subtotal	3,716,571	3,390,799	325,772	9.6
Eliminations	(9,842)	(2,569)	(7,273)	-
Corporate assets	248,551	160,973	87,578	54.4
Consolidated total	3,955,280	3,549,203	406,077	11.4

Depreciation and amortization, and Capital expenditures

Amount Unit: Millions of yen

	Year ended March 31, 2022 From April 1, 2021 to March 31, 2022	Year ended March 31, 2021 From April 1, 2020 to March 31, 2021	Change	
			Amount	%
Depreciation and amortization:				
Healthcare	44,541	39,657	4,884	12.3
Materials	32,364	29,779	2,585	8.7
Business Innovation	38,997	36,325	2,672	7.4
Imaging	14,121	14,946	(825)	(5.5)
Corporate	2,976	2,716	260	9.6
Consolidated total	132,999	123,423	9,576	7.8
Capital expenditures:				
Healthcare	103,896	51,324	52,572	102.4
Materials	31,694	24,906	6,788	27.3
Business Innovation	12,124	16,209	(4,085)	(25.2)
Imaging	5,534	7,213	(1,679)	(23.3)
Corporate	1,982	1,231	751	61.0
Consolidated total	155,230	100,883	54,347	53.9

(B) Geographic Information**a. Revenue**

Amount Unit: Millions of yen

	Year ended March 31, 2022 From April 1, 2021 to March 31, 2022		Year ended March 31, 2021 From April 1, 2020 to March 31, 2021		Change	
					Amount	%
Revenue:	%		%			
Japan:						
External customers	45.1	1,139,085	47.8	1,046,805	92,280	8.8
Intersegment		535,680		443,919	91,761	-
Total		1,674,765		1,490,724	184,041	12.3
The Americas:						
External customers	19.7	496,476	18.4	404,406	92,070	22.8
Intersegment		90,756		70,564	20,192	-
Total		587,232		474,970	112,262	23.6
Europe:						
External customers	12.8	323,518	11.4	250,501	73,017	29.1
Intersegment		18,102		12,857	5,245	-
Total		341,620		263,358	78,262	29.7
Asia and others:						
External customers	22.4	566,694	22.4	490,807	75,887	15.5
Intersegment		248,838		211,734	37,104	-
Total		815,532		702,541	112,991	16.1
Eliminations		(893,376)		(739,074)	(154,302)	-
Consolidated total	100.0	2,525,773	100.0	2,192,519	333,254	15.2

b. Operating income

Amount Unit: Millions of yen

	Year ended March 31, 2022 From April 1, 2021 to March 31, 2022		Year ended March 31, 2021 From April 1, 2020 to March 31, 2021		Change	
					Amount	%
Operating Income (Loss):	%		%			
Japan	7.2	119,858	6.4	95,838	24,020	25.1
The Americas	9.6	56,346	3.0	14,308	42,038	293.8
Europe	2.9	9,909	2.8	7,372	2,537	34.4
Asia and others	6.8	55,575	6.3	44,014	11,561	26.3
Eliminations		(11,986)		3,941	(15,927)	-
Consolidated total	9.1	229,702	7.5	165,473	64,229	38.8

c. Long - lived assets

Amount Unit: Millions of yen

	As of March 31, 2022	As of March 31, 2021	Change	
			Amount	%
Long - lived assets				
Japan	358,398	367,660	(9,262)	(2.5)
The Americas	137,069	90,885	46,184	50.8
Europe	180,298	122,356	57,942	47.4
Asia and others	61,074	54,350	6,724	12.4
Consolidated total	736,839	635,251	101,588	16.0

d. Overseas revenue (Destination Base)

Amount Unit: Millions of yen

	Year ended March 31, 2022 From April 1, 2021 to March 31, 2022		Year ended March 31, 2021 From April 1, 2020 to March 31, 2021		Change	
					Amount	%
Revenue:	%		%			
Domestic	39.3	991,885	42.3	927,910	63,975	6.9
Overseas:						
The Americas	20.7	522,362	19.0	416,341	106,021	25.5
Europe	13.4	337,408	12.2	267,902	69,506	25.9
Asia and others	26.6	674,118	26.5	580,366	93,752	16.2
Subtotal	60.7	1,533,888	57.7	1,264,609	269,279	21.3
Consolidated total	100.0	2,525,773	100.0	2,192,519	333,254	15.2

Note: The presentation of the Overseas Revenue (Destination Base) has been classified and disclosed based on the customer's location.

2. Three months ended March 31

(A) Operating Segment Information

Revenue

Amount Unit: Millions of yen

	Three months ended March 31, 2022 From January 1, 2022 to March 31, 2022		Three months ended March 31, 2021 From January 1, 2021 to March 31, 2021		Change	
					Amount	%
Revenue:	%		%			
Healthcare:						
External customers	33.9	225,015	30.9	191,230	33,785	17.7
Intersegment		36		26	10	-
Total		225,051		191,256	33,795	17.7
Materials:						
External customers	24.4	162,233	24.1	148,975	13,258	8.9
Intersegment		399		365	34	-
Total		162,632		149,340	13,292	8.9
Business Innovation:						
External customers	30.7	204,425	34.2	212,290	(7,865)	(3.7)
Intersegment		917		696	221	-
Total		205,342		212,986	(7,644)	(3.6)
Imaging:						
External customers	11.0	73,198	10.8	66,590	6,608	9.9
Intersegment		715		477	238	-
Total		73,913		67,067	6,846	10.2
Eliminations		(2,067)		(1,564)	(503)	-
Consolidated total	100.0	664,871	100.0	619,085	45,786	7.4

Note: The major products and services of each operating segment are as follows:

Healthcare:	Equipment and materials for medical systems, contract development and manufacturing organization of biopharmaceuticals, iPS cells (regenerative medicine), drug discovery support such as cell culture media and reagents, pharmaceuticals, cosmetics and supplements, etc.
Materials:	Electronic materials, display materials, industrial equipment, fine chemicals, recording media, equipment and materials for graphic communication, inks and industrial inkjet printheads, etc.
Business Innovation:	Digital MFPs, solutions and services, etc.
Imaging:	Instant photo systems, color films, services and equipment for photofinishing, digital cameras and optical devices, etc.

Overseas Revenue (Destination Base)

Amount Unit: Millions of yen

	Three months ended March 31, 2022 From January 1, 2022 to March 31, 2022		Three months ended March 31, 2021 From January 1, 2021 to March 31, 2021		Change	
					Amount	%
Revenue:	%		%			
Domestic	42.3	281,484	43.8	271,182	10,302	3.8
Overseas:						
The Americas	19.2	127,450	19.1	118,313	9,137	7.7
Europe	13.4	89,165	12.2	75,632	13,533	17.9
Asia and others	25.1	166,772	24.9	153,958	12,814	8.3
Subtotal	57.7	383,387	56.2	347,903	35,484	10.2
Consolidated total	100.0	664,871	100.0	619,085	45,786	7.4

Amounts Per Share of Common Stock

	Year ended March 31, 2022	Year ended March 31, 2021
	Yen	Yen
FUJIFILM Holdings shareholders' equity per share	6,244.29	5,514.11
Net income attributable to FUJIFILM Holdings per share	527.33	453.28
Net income attributable to FUJIFILM Holdings per share (Assuming full dilution)	526.11	451.75

Subsequent Event

Subsequent Event

The Company issued unsecured corporate bonds (with inter-bond pari passu clause) in April 2022 with plans to refinance existing investments related to M&A and capital expenditure to increase manufacturing capacity in the bio CDMO business. The outline is as follows.

The 16th Series of Unsecured Corporate Bonds (with inter-bond pari passu clause) (Social Bonds)

- 1.Total amount of issue: 40 billion yen
- 2.Issue price: 100 yen per face value of 100 yen
- 3.Closing date: April 20, 2022
- 4.Interest rate: 0.100% per annum
- 5.Redemption method and maturity date: The Bonds will be redeemed in full on April 18, 2025

The 17th Series of Unsecured Corporate Bonds (with inter-bond pari passu clause) (Social Bonds)

- 1.Total amount of issue: 40 billion yen
- 2.Issue price: 100 yen per face value of 100 yen
- 3.Closing date: April 20, 2022
- 4.Interest rate: 0.195% per annum
- 5.Redemption method and maturity date: The Bonds will be redeemed in full on April 20, 2027

The 18th Series of Unsecured Corporate Bonds (with inter-bond pari passu clause) (Social Bonds)

- 1.Total amount of issue: 20 billion yen
- 2.Issue price: 100 yen per face value of 100 yen
- 3.Closing date: April 20, 2022
- 4.Interest rate: 0.304% per annum
- 5.Redemption method and maturity date: The Bonds will be redeemed in full on April 20, 2029

The 19th Series of Unsecured Corporate Bonds (with inter-bond pari passu clause) (Social Bonds)

- 1.Total amount of issue: 20 billion yen
- 2.Issue price: 100 yen per face value of 100 yen
- 3.Closing date: April 20, 2022
- 4.Interest rate: 0.374% per annum
- 5.Redemption method and maturity date: The Bonds will be redeemed in full on April 20, 2032